Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 4/20 | 0.64 |
| ▸ | ABL1 | P00519 | 1/20 | 0.62 |
| ▸ | BCR | P11274 | 1/20 | 0.62 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.55 |
| ▸ | KDR | P35968 | 2/20 | 0.55 |
| ▸ | KIT | P10721 | 6/20 | 0.53 |
| ▸ | FLT3 | P36888 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
| ▸ | F10 | P00742 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL740517 | 0.92 | AURKA (0.65) | AURKAABL1BCRFGFR1KDR | |
| SCHEMBL739540 | 0.92 | AURKA (0.54) | AURKAABL1BCRFGFR1KDR | |
| SCHEMBL740985 | 0.91 | AURKA (0.77) | AURKAABL1BCRKITFLT3 | |
| SCHEMBL740888 | 0.90 | AURKA (0.66) | AURKAABL1BCRFGFR1KDR | |
| SCHEMBL741392 | 0.88 | FLT3 (0.51) | AURKAABL1BCRFGFR1KDR | |
| SCHEMBL740045 | 0.88 | AURKA (0.60) | AURKAABL1BCRFGFR1KDR | |
| SCHEMBL740102 | 0.87 | AURKA (0.65) | AURKAABL1BCRFGFR1KDR | |
| SCHEMBL1779351 | 0.86 | AURKA (0.69) | AURKAABL1BCRKITFLT3 | |
| SCHEMBL739851 | 0.86 | AURKA (0.65) | AURKAABL1BCRKITFLT3 | |
| SCHEMBL742821 | 0.86 | AURKA (0.65) | AURKAABL1BCRKITFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138217-B2 | Aurora kinase inhibitors; proliferative disorders; anticancer agents; antitumor agents; N-(1-methyl-1-phenylethyl)-3-((4-morpholin-4-ylbenzoyl)amino)-1H-thieno(2,3-c)pyrazole-5-carboxamide | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-03-20 | — | — | US | claimed |
| EP-1711177-B1 | 1H-THIENO 2,3-c PYRAZOLE DERIVATIVES USEFUL AS KINASE I INHIBITORS | PFIZER ITALIA SRL (IT) | 2008-05-28 | — | — | EP | claimed |
| EP-1711177-A1 | 1H-THIENO 2,3-c PYRAZOLE DERIVATIVES USEFUL AS KINASE I INHIBITORS | Pfizer Italia S.r.l. (IT) | 2006-10-18 | — | — | EP | claimed |
| US-20050187209-A1 | 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2005-08-25 | — | — | US | claimed |
| WO-2005074922-A1 | 1H-THIENO[2,3-c]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS | PFIZER ITALIA S.R.L. (IT) | 2005-08-18 | — | — | WO | claimed |
| US-8481584-B2 | 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-07-09 | — | — | US | disclosed |
| US-20120165311-A1 | 1H-THIENO[2,3-C]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-06-28 | — | — | US | disclosed |
| US-8138217-B2 | Aurora kinase inhibitors; proliferative disorders; anticancer agents; antitumor agents; N-(1-methyl-1-phenylethyl)-3-((4-morpholin-4-ylbenzoyl)amino)-1H-thieno(2,3-c)pyrazole-5-carboxamide | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-03-20 | — | — | US | disclosed |
| EP-1711177-B1 | 1H-THIENO 2,3-c PYRAZOLE DERIVATIVES USEFUL AS KINASE I INHIBITORS | PFIZER ITALIA SRL (IT) | 2008-05-28 | — | — | EP | disclosed |
| EP-1711177-A1 | 1H-THIENO 2,3-c PYRAZOLE DERIVATIVES USEFUL AS KINASE I INHIBITORS | Pfizer Italia S.r.l. (IT) | 2006-10-18 | — | — | EP | disclosed |
| US-20050187209-A1 | 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors | PHARMACIA ITALIA S.P.A. (IT) | 2005-08-25 | — | — | US | disclosed |
| WO-2005074922-A1 | 1H-THIENO[2,3-c]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS | PFIZER ITALIA S.R.L. (IT) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165311-A1 | 1H-THIENO[2,3-C]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS | MAP3K19, MAP3K1, MAP3K3 | AURKA 349/4885ABL1 151/4885BCR 942/4885 |
| US-20050187209-A1 | 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors | MAP3K19, MAP3K1, MAP3K3 | AURKA 340/4885ABL1 149/4885BCR 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.